Related Experiment Videos
Inhibition of intratracheal lung cancer development by systemic delivery of E1A
1Department of Tumor Biology and Breast Cancer Basic Research Program, The University of Texas MD Anderson Cancer Center, Houston 77030, USA.
Abstract:
Amplification or overexpression of HER-2/neu in human lung cancer has been correlated with poor prognosis and chemoresistance. We have previously reported that the adenovirus type 5 early region 1A (E1A) gene product can suppress HER-2/neu-mediated transformation phenotypes through inhibition of HER-2/neu expression. To find an efficient way to treat HER-2/neu-overexpressing lung cancer with E1A, a replication-deficient adenovirus containing the E1A gene, Ad.E1A(+), was used to transduce E1A into HER-2/neu-overexpressing and low expressing human lung cancer cell lines. Tumour cell growth in vitro and colony formation in soft agarose were greatly inhibited by Ad.E1A(+) transduction in HER-2/neu-overexpressing lung cancer cell lines. In HER-2/neu low expressing cell lines, E1A could not inhibit cell growth in vitro but could reduce the colony formation ability in soft agarose, indicating different effects of E1A in these two types of cancer cells. To test the therapeutic efficacy of E1A to lung cancer by systemic delivery in vivo, tumor-bearing mice were established by intratracheal injection of lung cancer cells and treated by i.v. tail injections of Ad.E1A(+). As a result, Ad.E1A(+) suppressed HER-2/neu overexpression and inhibited intratracheal lung cancer growth. However, no significant tumor suppression effect of Ad.E1A(+) was observed in mice bearing HER-2/neu low expressing cell line when the same therapeutic procedure was followed. Thus, we conclude that systemic delivery of Ad.E1A(+) can efficiently achieve therapeutic effect in HER-2/neu-overexpressing lung cancer in vivo.
Insights
Adenovirus type 5 E1A gene therapy effectively treats HER-2/neu-overexpressing lung cancer. Systemic delivery of Ad.E1A(+) suppressed tumor growth in mice, highlighting its therapeutic potential for this specific cancer subtype.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- HER-2/neu amplification in lung cancer correlates with poor prognosis and chemoresistance.
- The adenovirus type 5 early region 1A (E1A) gene product can inhibit HER-2/neu expression and transformation.
- Targeting HER-2/neu overexpression is a potential therapeutic strategy for lung cancer.
Purpose of the Study:
- To evaluate the therapeutic efficacy of Ad.E1A(+) in treating HER-2/neu-overexpressing lung cancer.
- To investigate the effects of E1A gene transduction on lung cancer cell growth in vitro and in vivo.
- To determine if systemic delivery of Ad.E1A(+) can suppress tumor growth in a HER-2/neu-dependent manner.
Main Methods:
- Replication-deficient adenovirus Ad.E1A(+) was used to transduce E1A into HER-2/neu-overexpressing and low-expressing human lung cancer cell lines.
- In vitro studies assessed tumor cell growth and colony formation in soft agarose.
- In vivo studies involved establishing lung cancer xenografts in mice and treating them with systemic Ad.E1A(+) via intravenous tail injections.
Main Results:
- Ad.E1A(+) significantly inhibited tumor cell growth and colony formation in HER-2/neu-overexpressing lung cancer cell lines in vitro.
- In vivo, Ad.E1A(+) suppressed HER-2/neu overexpression and inhibited intratracheal lung cancer growth in tumor-bearing mice.
- No significant tumor suppression was observed in mice with HER-2/neu low-expressing lung cancer cell lines, indicating a selective therapeutic effect.
Conclusions:
- Systemic delivery of Ad.E1A(+) demonstrates efficient therapeutic effects specifically in HER-2/neu-overexpressing lung cancer.
- E1A gene therapy holds promise as a targeted treatment for lung cancers with HER-2/neu amplification.
- The findings support the development of Ad.E1A(+) as a potential therapeutic agent for specific lung cancer patient populations.